Inauhzin and Nutlin3 synergistically activate p53 and suppress tumor growth

Yiwei Zhang, Qi Zhang, Shelya X. Zeng, Yu Zhang, Lindsey Mayo, Hua Lu

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Several proteins have been suggested in promoting tumor formation in numerous human tissues by inactivating the tumor suppressor p53. This has generated interest in the development of small molecules to block these inhibitors of p53 and to regain p53 activity. Recently, we identified a small molecule, Inauhzin, which can inhibit SIRT1 activity and activate p53. SIRT1 is a deacetylase that deacetylates p53 and facilitates Mdm2 mediated p53 destabilization. In this study, we tested if combining Inauhzin with Nutlin-3, an inhibitor of MDM2-p53 binding, might synergistically activate p53 to suppress tumor growth. Indeed, at lower doses, combination of Inauhzin and Nutlin-3 exhibited a synergistic effect on inhibiting cell growth and promoting apoptosis in human colon and lung cancer cell lines in a p53-dependent fashion. Minimal effects were observed with treatment of either compound alone. Using a xenograft tumor model, we also showed a synergistic effect with both compounds. Thus, to fully regain p53 activity, targeting its multiple inhibitory proteins might be a better approach. Our study provides evidence supporting this concept for achieving better therapeutic efficacy in tumors that possess wild type p53.

Original languageEnglish
Pages (from-to)915-924
Number of pages10
JournalCancer Biology and Therapy
Volume13
Issue number10
DOIs
StatePublished - Aug 2012

Fingerprint

Growth
Neoplasms
Heterografts
Colonic Neoplasms
Lung Neoplasms
Proteins
10-(2-(5H-(1,2,4)triazino(5,6-b)indol-3-ylthio)butanoyl)-10H-phenothiazine
Apoptosis
Cell Line
nutlin 3
Therapeutics

Keywords

  • Acetylation
  • Apoptosis
  • Deacetylation
  • Inauhzin
  • MDM2
  • Nutlin-3
  • p53
  • Small molecule inhibitor
  • Xenograft tumor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Molecular Medicine
  • Pharmacology

Cite this

Inauhzin and Nutlin3 synergistically activate p53 and suppress tumor growth. / Zhang, Yiwei; Zhang, Qi; Zeng, Shelya X.; Zhang, Yu; Mayo, Lindsey; Lu, Hua.

In: Cancer Biology and Therapy, Vol. 13, No. 10, 08.2012, p. 915-924.

Research output: Contribution to journalArticle

Zhang, Yiwei ; Zhang, Qi ; Zeng, Shelya X. ; Zhang, Yu ; Mayo, Lindsey ; Lu, Hua. / Inauhzin and Nutlin3 synergistically activate p53 and suppress tumor growth. In: Cancer Biology and Therapy. 2012 ; Vol. 13, No. 10. pp. 915-924.
@article{e7a3f7ea296d43a1a95a52020b7ef24a,
title = "Inauhzin and Nutlin3 synergistically activate p53 and suppress tumor growth",
abstract = "Several proteins have been suggested in promoting tumor formation in numerous human tissues by inactivating the tumor suppressor p53. This has generated interest in the development of small molecules to block these inhibitors of p53 and to regain p53 activity. Recently, we identified a small molecule, Inauhzin, which can inhibit SIRT1 activity and activate p53. SIRT1 is a deacetylase that deacetylates p53 and facilitates Mdm2 mediated p53 destabilization. In this study, we tested if combining Inauhzin with Nutlin-3, an inhibitor of MDM2-p53 binding, might synergistically activate p53 to suppress tumor growth. Indeed, at lower doses, combination of Inauhzin and Nutlin-3 exhibited a synergistic effect on inhibiting cell growth and promoting apoptosis in human colon and lung cancer cell lines in a p53-dependent fashion. Minimal effects were observed with treatment of either compound alone. Using a xenograft tumor model, we also showed a synergistic effect with both compounds. Thus, to fully regain p53 activity, targeting its multiple inhibitory proteins might be a better approach. Our study provides evidence supporting this concept for achieving better therapeutic efficacy in tumors that possess wild type p53.",
keywords = "Acetylation, Apoptosis, Deacetylation, Inauhzin, MDM2, Nutlin-3, p53, Small molecule inhibitor, Xenograft tumor",
author = "Yiwei Zhang and Qi Zhang and Zeng, {Shelya X.} and Yu Zhang and Lindsey Mayo and Hua Lu",
year = "2012",
month = "8",
doi = "10.4161/cbt.20844",
language = "English",
volume = "13",
pages = "915--924",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "10",

}

TY - JOUR

T1 - Inauhzin and Nutlin3 synergistically activate p53 and suppress tumor growth

AU - Zhang, Yiwei

AU - Zhang, Qi

AU - Zeng, Shelya X.

AU - Zhang, Yu

AU - Mayo, Lindsey

AU - Lu, Hua

PY - 2012/8

Y1 - 2012/8

N2 - Several proteins have been suggested in promoting tumor formation in numerous human tissues by inactivating the tumor suppressor p53. This has generated interest in the development of small molecules to block these inhibitors of p53 and to regain p53 activity. Recently, we identified a small molecule, Inauhzin, which can inhibit SIRT1 activity and activate p53. SIRT1 is a deacetylase that deacetylates p53 and facilitates Mdm2 mediated p53 destabilization. In this study, we tested if combining Inauhzin with Nutlin-3, an inhibitor of MDM2-p53 binding, might synergistically activate p53 to suppress tumor growth. Indeed, at lower doses, combination of Inauhzin and Nutlin-3 exhibited a synergistic effect on inhibiting cell growth and promoting apoptosis in human colon and lung cancer cell lines in a p53-dependent fashion. Minimal effects were observed with treatment of either compound alone. Using a xenograft tumor model, we also showed a synergistic effect with both compounds. Thus, to fully regain p53 activity, targeting its multiple inhibitory proteins might be a better approach. Our study provides evidence supporting this concept for achieving better therapeutic efficacy in tumors that possess wild type p53.

AB - Several proteins have been suggested in promoting tumor formation in numerous human tissues by inactivating the tumor suppressor p53. This has generated interest in the development of small molecules to block these inhibitors of p53 and to regain p53 activity. Recently, we identified a small molecule, Inauhzin, which can inhibit SIRT1 activity and activate p53. SIRT1 is a deacetylase that deacetylates p53 and facilitates Mdm2 mediated p53 destabilization. In this study, we tested if combining Inauhzin with Nutlin-3, an inhibitor of MDM2-p53 binding, might synergistically activate p53 to suppress tumor growth. Indeed, at lower doses, combination of Inauhzin and Nutlin-3 exhibited a synergistic effect on inhibiting cell growth and promoting apoptosis in human colon and lung cancer cell lines in a p53-dependent fashion. Minimal effects were observed with treatment of either compound alone. Using a xenograft tumor model, we also showed a synergistic effect with both compounds. Thus, to fully regain p53 activity, targeting its multiple inhibitory proteins might be a better approach. Our study provides evidence supporting this concept for achieving better therapeutic efficacy in tumors that possess wild type p53.

KW - Acetylation

KW - Apoptosis

KW - Deacetylation

KW - Inauhzin

KW - MDM2

KW - Nutlin-3

KW - p53

KW - Small molecule inhibitor

KW - Xenograft tumor

UR - http://www.scopus.com/inward/record.url?scp=84864531616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864531616&partnerID=8YFLogxK

U2 - 10.4161/cbt.20844

DO - 10.4161/cbt.20844

M3 - Article

VL - 13

SP - 915

EP - 924

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 10

ER -